Howland Capital Management LLC lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,977 shares of the medical equipment provider’s stock after selling 68 shares during the period. Howland Capital Management LLC’s holdings in Zimmer Biomet Holdings were worth $896,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in the stock. Alpha Windward LLC boosted its position in shares of Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock worth $202,000 after buying an additional 18 shares during the last quarter. Sandy Spring Bank boosted its position in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares in the last quarter. Cleararc Capital Inc. boosted its position in Zimmer Biomet Holdings by 0.5% in the first quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock worth $598,000 after buying an additional 25 shares in the last quarter. Finally, Enterprise Financial Services Corp boosted its position in Zimmer Biomet Holdings by 1.0% in the first quarter. Enterprise Financial Services Corp now owns 2,637 shares of the medical equipment provider’s stock worth $322,000 after buying an additional 27 shares in the last quarter. 82.84% of the stock is owned by institutional investors and hedge funds.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 111.38 on Friday. The firm has a 50-day moving average price of $122.63 and a 200-day moving average price of $121.15. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The company has a market cap of $22.52 billion, a P/E ratio of 31.72 and a beta of 1.20.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. The company had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the prior year, the business posted $2.02 earnings per share. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.
COPYRIGHT VIOLATION NOTICE: “Howland Capital Management LLC Lowers Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)” was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/howland-capital-management-llc-lowers-position-in-zimmer-biomet-holdings-inc-nysezbh-updated-updated.html.
ZBH has been the topic of a number of recent research reports. Oppenheimer Holdings, Inc. set a $137.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Monday, August 14th. BidaskClub lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Canaccord Genuity reissued a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. BMO Capital Markets lifted their price target on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. Finally, Cantor Fitzgerald set a $137.00 price objective on Zimmer Biomet Holdings and gave the stock a “hold” rating in a research note on Thursday, July 27th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $136.90.
In related news, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.